ImmunoPrecise Antibodies (IPA) has released an update.
ImmunoPrecise Antibodies has secured a financing deal with Yorkville Advisors for up to $3 million in convertible debentures, aimed at bolstering the company’s capital. The agreement includes two tranches, with the first already completed and the second contingent on SEC regulatory approval. These debentures can be converted into common shares, subject to terms including interest rates and potential redemption premiums.
For further insights into IPA stock, check out TipRanks’ Stock Analysis page.
